Novel	0	5	O
biological	6	16	O
agents	17	23	O
for	24	27	O
the	28	31	O
treatment	32	41	O
of	42	44	O
hormone	45	52	B-Pathological_formation
-	52	53	I-Pathological_formation
refractory	53	63	I-Pathological_formation
prostate	64	72	I-Pathological_formation
cancer	73	79	I-Pathological_formation
(	80	81	O
HRPC	81	85	B-Pathological_formation
)	85	86	O
.	86	87	O

Hormone	89	96	B-Pathological_formation
-	96	97	I-Pathological_formation
refractory	97	107	I-Pathological_formation
prostate	108	116	I-Pathological_formation
cancer	117	123	I-Pathological_formation
(	124	125	O
HRPC	125	129	B-Pathological_formation
)	129	130	O
is	131	133	O
an	134	136	O
inevitable	137	147	O
evolution	148	157	O
of	158	160	O
prostate	161	169	B-Organ
carcinogenesis	170	184	O
,	184	185	O
through	186	193	O
which	194	199	O
the	200	203	O
normal	204	210	O
dependence	211	221	O
on	222	224	O
hormones	225	233	O
for	234	237	O
growth	238	244	O
and	245	248	O
survival	249	257	O
is	258	260	O
bypassed	261	269	O
.	269	270	O

Although	271	279	O
advances	280	288	O
in	289	291	O
terms	292	297	O
of	298	300	O
symptoms	301	309	O
palliation	310	320	O
and	321	324	O
quality	325	332	O
of	333	335	O
life	336	340	O
improvement	341	352	O
have	353	357	O
been	358	362	O
addressed	363	372	O
with	373	377	O
current	378	385	O
treatment	386	395	O
options	396	403	O
,	403	404	O
innovative	405	415	O
approaches	416	426	O
are	427	430	O
needed	431	437	O
to	438	440	O
improve	441	448	O
survival	449	457	O
rates	458	463	O
.	463	464	O

A	465	466	O
thorough	467	475	O
understanding	476	489	O
of	490	492	O
HRPC	493	497	B-Pathological_formation
-	497	498	O
associated	498	508	O
molecular	509	518	O
pathways	519	527	O
and	528	531	O
mechanisms	532	542	O
of	543	545	O
resistance	546	556	O
are	557	560	O
a	561	562	O
prerequisite	563	575	O
for	576	579	O
novel	580	585	O
potential	586	595	O
therapeutic	596	607	O
interventions	608	621	O
.	621	622	O

Preclinical	623	634	O
and	635	638	O
early	639	644	O
clinical	645	653	O
studies	654	661	O
are	662	665	O
ongoing	666	673	O
to	674	676	O
evaluate	677	685	O
new	686	689	O
therapies	690	699	O
that	700	704	O
target	705	711	O
specific	712	720	O
molecular	721	730	O
entities	731	739	O
.	739	740	O

Agents	741	747	O
under	748	753	O
development	754	765	O
include	766	773	O
growth	774	780	O
factor	781	787	O
receptor	788	796	O
inhibitors	797	807	O
,	807	808	O
small	809	814	O
molecules	815	824	O
targeting	825	834	O
signal	835	841	O
transduction	842	854	O
pathways	855	863	O
,	863	864	O
apoptosis	865	874	O
and	875	878	O
cell	879	883	B-Cell
-	883	884	O
cycle	884	889	O
regulators	890	900	O
,	900	901	O
angiogenesis	902	914	O
and	915	918	O
metastasis	919	929	O
inhibitors	930	940	O
,	940	941	O
differentiation	942	957	O
agents	958	964	O
,	964	965	O
telomerase	966	976	B-Gene_or_gene_product
inactivators	977	989	O
,	989	990	O
and	991	994	O
epigenetic	995	1005	O
therapeutics	1006	1018	O
.	1018	1019	O

Incorporation	1020	1033	O
of	1034	1036	O
these	1037	1042	O
agents	1043	1049	O
into	1050	1054	O
existing	1055	1063	O
treatment	1064	1073	O
regimens	1074	1082	O
will	1083	1087	O
guide	1088	1093	O
us	1094	1096	O
in	1097	1099	O
the	1100	1103	O
development	1104	1115	O
of	1116	1118	O
a	1119	1120	O
multidisciplinary	1121	1138	O
treatment	1139	1148	O
strategy	1149	1157	O
of	1158	1160	O
HRPC	1161	1165	B-Pathological_formation
.	1165	1166	O

This	1167	1171	O
article	1172	1179	O
critically	1180	1190	O
reviews	1191	1198	O
published	1199	1208	O
data	1209	1213	O
on	1214	1216	O
new	1217	1220	O
biological	1221	1231	O
agents	1232	1238	O
that	1239	1243	O
are	1244	1247	O
being	1248	1253	O
tested	1254	1260	O
in	1261	1263	O
HRPC	1264	1268	B-Pathological_formation
clinical	1269	1277	O
trials	1278	1284	O
,	1284	1285	O
highlights	1286	1296	O
ongoing	1297	1304	O
research	1305	1313	O
and	1314	1317	O
considers	1318	1327	O
the	1328	1331	O
future	1332	1338	O
perspectives	1339	1351	O
of	1352	1354	O
this	1355	1359	O
new	1360	1363	O
class	1364	1369	O
of	1370	1372	O
agents	1373	1379	O
.	1379	1380	O

